Targeting Glioma Stem Cells by Functional Inhibition of Dynamin 2: A Novel Treatment Strategy for Glioblastoma.

Targeting Glioma Stem Cells by Functional Inhibition of Dynamin 2: A Novel Treatment Strategy for Glioblastoma. Cancer Invest. 2019 Mar 25;:1-12 Authors: Luwor R, Morokoff AP, Amiridis S, D'Abaco G, Paradiso L, Stylli SS, Nguyen HPT, Tarleton M, Young KA, O'Brien TJ, Robinson PJ, Chircop M, McCluskey A, Jones NC Abstract Glioma stem cells (GSCs) play major roles in drug resistance, tumour maintenance and recurrence of glioblastoma. We investigated inhibition of the GTPase dynamin 2 as a therapy for glioblastoma. Glioma cell lines and patient-derived GSCs were treated with dynamin inhibitors, Dynole 34-2 and CyDyn 4-36. We studied about cell viability, and GSC neurosphere formation in vitro and orthotopic tumour growth in vivo. Dynamin inhibition reduced glioblastoma cell line viability and suppressed neurosphere formation and migration of GSCs. Tumour growth was reduced by CyDyn 4-36 treatment. Dynamin 2 inhibition therefore represents a novel approach for stem cell-directed Glioblastoma therapy. PMID: 30907150 [PubMed - as supplied by publisher]
Source: Cancer Investigation - Category: Cancer & Oncology Tags: Cancer Invest Source Type: research